(BFM Bourse) – The Nantes biotechnology company announced on Tuesday evening that it had expanded its patent portfolio internationally. OSE Immunotherapeutics has indeed obtained a new patent in the United States which reinforces the protection of Tedopi, its potential therapeutic vaccine against non-small cell lung cancer.
After Medesis Pharma on Tuesday, it is the turn of another French company in the field of sciences and life to be granted a patent to protect its therapeutic option on American soil.
OSE Immunotherapeutics announced Tuesday evening that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi, the group’s most advanced molecule. It is used in a therapeutic vaccine, for the treatment of certain patients with non-small cell lung cancer (NSCLC) after failure of immunotherapy.
NSCLC represents 85% to 90% of all lung cancers in Europe. The 5-year survival rate for metastatic NSCLC is 7%, according to data from the American Cancer Society.
This new patent granted by this authority recognizes the innovative nature of a multi-epitope combination (all the peptides making up Tedopi) administered after failure of treatment with a PD-1/PD-L1 checkpoint inhibitor in patients presenting with a phenotype HLA-A2+ with non-small cell lung cancer. It also reinforces “the value of Tedopi, and ensures the protection of the product in the United States until 2037”, adds OSE Therapeutics.
For the company, this precious sesame “represents an additional step in the clinical development of the product based on the positive results of the first phase III clinical study (last stage of clinical trials before potential marketing, editor’s note) in lung cancer not small cells, in secondary resistance after escape from checkpoint inhibitors”.
OSE Immunotherapeutics adds that this family of patents, focused on the same target population, has been filed internationally in many other countries and has already been granted in Japan.
On the Paris Stock Exchange, OSE Immunotherapeutics jumped 13% to 3.90 euros, after gaining more than 28% to 4.43 euros, around 9:15 a.m., following the obtaining of this new patent on American soil.
Financial support from Bpifrance
At the end of June, OSE Immunotherapeutics obtained a loan of 1.5 million euros from Bpifrance to accelerate the development of a companion diagnostic test associated with its therapeutic vaccine Tedopi, in lung cancer.
This companion test is “a diagnostic test which makes it possible to determine which subgroup of patients is likely to benefit from treatment with a given molecule and which subgroup is not”, according to the definition of the High Authority for Health. And in the case of OSE Immunotherapeutics, it makes it possible to determine the presence or absence of the HLA-A2 + phenotype which respond favorably to Tedopi. This marker is present in 45% of all patients with non-small cell lung cancer.
The amount of funding “should cover all of the development costs of the test whose HLA-A2 methods have already been identified”, explained Invest Securities at the time, in a note published in response to obtaining this funding.
For its part, Degroof Petercam estimated in October 2022 that sales of Tedopi could ultimately reach a peak of around 300 million euros.
In addition to non-small cell lung cancer, OSE Immunotherapeutics is conducting other Phase II clinical trials (intermediate stage of clinical trials) evaluating Tedopi for other indications, namely pancreatic cancer and ovarian cancer. .
Sabrina Sadgui – ©2023 BFM Bourse
Are you following this action?
Receive all the information about OSE IMMUNO in real time: